NAVCO Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 1/6
NAVCO Pharmaceuticals has a total shareholder equity of CA$197.4K and total debt of CA$610.4K, which brings its debt-to-equity ratio to 309.3%. Its total assets and total liabilities are CA$1.0M and CA$839.1K respectively.
Key information
309.3%
Debt to equity ratio
CA$610.38k
Debt
Interest coverage ratio | n/a |
Cash | CA$21.49k |
Equity | CA$197.36k |
Total liabilities | CA$839.10k |
Total assets | CA$1.04m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: F0U's short term assets (CA$185.0K) do not cover its short term liabilities (CA$755.0K).
Long Term Liabilities: F0U's short term assets (CA$185.0K) exceed its long term liabilities (CA$84.1K).
Debt to Equity History and Analysis
Debt Level: F0U's net debt to equity ratio (298.4%) is considered high.
Reducing Debt: Insufficient data to determine if F0U's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: F0U has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: F0U has less than a year of cash runway if free cash flow continues to reduce at historical rates of 67.8% each year